Free Trial
NASDAQ:VRDN

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

Viridian Therapeutics logo
$17.04 -0.09 (-0.53%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$17.05 +0.01 (+0.03%)
As of 07/11/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Key Stats

Today's Range
$16.78
$17.39
50-Day Range
$12.03
$17.13
52-Week Range
$9.90
$27.20
Volume
477,598 shs
Average Volume
1.15 million shs
Market Capitalization
$1.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.56
Consensus Rating
Moderate Buy

Company Overview

Viridian Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

VRDN MarketRank™: 

Viridian Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 380th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Viridian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Viridian Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Viridian Therapeutics are expected to decrease in the coming year, from ($4.03) to ($4.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viridian Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viridian Therapeutics is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viridian Therapeutics has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Viridian Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.14% of the float of Viridian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viridian Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viridian Therapeutics has recently decreased by 84.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Viridian Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viridian Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.14% of the float of Viridian Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Viridian Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viridian Therapeutics has recently decreased by 84.83%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Viridian Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Viridian Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VRDN Stock News Headlines

Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
Viridian Therapeutics: The Song Remains The Same
See More Headlines

VRDN Stock Analysis - Frequently Asked Questions

Viridian Therapeutics' stock was trading at $19.17 on January 1st, 2025. Since then, VRDN shares have decreased by 11.1% and is now trading at $17.04.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics's revenue for the quarter was up .0% compared to the same quarter last year.

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viridian Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
7/13/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Healthcare
Current Symbol
NASDAQ:VRDN
CIK
1590750
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$61.00
Low Price Target
$27.00
Potential Upside/Downside
+120.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$269.95 million
Net Margins
-102,092.39%
Pretax Margin
-102,092.39%
Return on Equity
-70.61%
Return on Assets
-44.67%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
19.49
Quick Ratio
19.49

Sales & Book Value

Annual Sales
$300 thousand
Price / Sales
4,634.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.09 per share
Price / Book
2.80

Miscellaneous

Outstanding Shares
81,590,000
Free Float
80,303,000
Market Cap
$1.39 billion
Optionable
Optionable
Beta
0.39
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:VRDN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners